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Abstract 48 
Background 49 
Neuropsychological investigations can help untangle the etiological and phenomenological 50 
heterogeneity of schizophrenia, but have scarcely been employed in the context of treatment-51 
resistant schizophrenia. No population-based study has examined neuropsychological function in the 52 
first-episode of treatment-resistant psychosis.  53 
Methods 54 
We report baseline neuropsychological findings from a longitudinal, population-based study of first-55 
episode psychosis, which followed up cases from index admission to 10 years. At the 10-year follow 56 
up patients were classified as treatment responsive or treatment resistant after reconstructing their 57 
entire case histories. Of 145 cases with neuropsychological data at baseline, 113 were classified as 58 
treatment responsive, and 32 as treatment resistant at the 10-year follow-up.  59 
Results 60 
Compared to 257 community controls, both case groups showed baseline deficits in three composite 61 
neuropsychological scores, derived from principal component analysis: verbal intelligence and 62 
fluency, visuospatial ability and executive function, and verbal memory and learning (P values≤0.001). 63 
Compared to treatment responders, treatment-resistant cases showed deficits in verbal intelligence 64 
and fluency, both in the extended psychosis sample (t=-2.32; P=0.022) and in the schizophrenia 65 
diagnostic subgroup (t=-2.49; P=0.017). Similar relative deficits in the treatment-resistant cases 66 
emerged in sub-/sensitivity analyses excluding patients with delayed-onset treatment resistance (P 67 
values<0.01-0.001) and those born outside the UK (P values<0.05).  68 
Conclusions 69 
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Verbal intelligence and fluency are impaired in patients with treatment-resistant psychosis compared 70 
to those who respond to treatment. This differential is already detectable – at a group level - at the 71 
first illness episode, supporting the conceptualisation of treatment-resistant psychosis as a severe, 72 
pathogenically distinct variant, embedded in aberrant neurodevelopmental processes. 73 
 74 
Keywords: Cohort study; population-based; psychosis; schizophrenia; first episode; treatment 75 
resistant; neuropsychological 76 
 77 
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 95 
Introduction  96 
Schizophrenia and other psychoses are severe neuropsychiatric disorders, heterogeneous in aetiology, 97 
clinical trajectory and treatment response (Fanous & Kendler, 2005; van Os, 2016). In approximately 98 
30% of schizophrenia patients, psychotic symptoms respond poorly, if at all, to most antipsychotics, 99 
with the notable exception of clozapine (Elkis & Buckley, 2016; Howes et al. 2017; Gillespie et al. 2017). 100 
This emerged as the gold-standard pharmacological intervention for ‘treatment-resistant 101 
schizophrenia’ (TRS) in 1988 (Kane et al. 1988). Since then, studies have varied considerably in their 102 
definitions of TRS (Howes et al. 2017), although there is a consistent minimum requirement of two 103 
periods of adherence to two different antipsychotics, each administered at adequate doses (variously 104 
defined) for at least 4 weeks, resulting in symptom reductions of less than 20% (Gillespie et al. 2017).  105 
Recent evidence suggests that TRS is neurobiologically and categorically distinct from 106 
treatment-responsive schizophrenia (Gillespie et al. 2017). Unlike treatment-responsive patients, 107 
treatment-resistant (TR) ones do not exhibit elevation in dopamine synthesis capacity (Demjaha et al. 108 
2012), and instead, show elevated glutamate levels in the anterior cingulate cortex (Demjaha et al. 109 
2014). In addition, previous findings from the ÆSOP-10 study (Aetiology and Ethnicity in Schizophrenia 110 
and Other Psychoses) by our group showed that 84% of TR patients were resistant from illness onset 111 
(primary TRS), while the remaining 16% made an initial response to antipsychotics, but became TR 112 
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later (secondary TRS) (Demjaha et al. 2017). Lally and colleagues (2016) showed similar results in the 113 
GAP (Genetics and Psychosis) first-episode study, with 70% of TR patients having primary TRS.  114 
Despite emerging evidence that specific combinations of cognitive deficits define disease 115 
heterogeneity as related to treatment response (Gilbert et al. 2014), neuropsychological 116 
investigations largely remain an untapped resource for characterising the origin and mechanism of 117 
TRS. To date, only six studies have compared neuropsychological function between treatment-118 
resistant and treatment-responsive patients with psychosis, showing the former to have consistent 119 
relative deficits in verbal domains, such as language, verbal intelligence, verbal memory, verbal 120 
fluency and verbal interference (Joober et al. 2002; de Bartolomeis et al. 2013; Iasevoli et al. 2016), 121 
less consistently reported deficits in nonverbal domains, such as performance intelligence, processing 122 
speed, visuospatial function and visual memory (Joober et al. 2002; Bourque et al. 2013; Frydecka et 123 
al. 2016), and no cognitive differences from treatment-responsive patients in one study (Anderson et 124 
al. 2015).  125 
All the above studies have involved cross-sectional investigations of chronically ill samples 126 
with schizophrenia or schizoaffective disorder, and with established group differences in treatment 127 
response and medication profiles. The respective research designs and methodologies have allowed 128 
limited conclusions with regard to two important questions: 1) Do neuropsychological differences 129 
between treatment-resistant and treatment-responsive individuals reflect premorbid differences, or 130 
the impact of non-remitting psychosis? 2) Do findings from TRS generalise to other psychoses? 131 
To address these questions, we examined baseline neuropsychological data from ÆSOP-10, a 132 
population-based study of first-episode psychosis with a 10-year follow-up (Fearon et al. 2006; 133 
Morgan et al. 2006; Morgan et al. 2014). All neuropsychological assessments were carried out during 134 
the patients’ first episode of psychosis, approximately 10 years before participants were characterised 135 
as TR or treatment responsive following detailed re-constructions of their case histories by the ÆSOP 136 
team (Demjaha et al. 2017). In line with the TRS literature and with additional neuropsychological 137 
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findings in support of dimensional models of psychosis (Kravariti et al. 2012), we predicted that TR 138 
patients would show deficits in verbal tasks of intelligence, fluency and memory compared to 139 
treatment-responsive patients and community controls, both among participants with schizophrenia 140 
and in the extended sample with various psychoses.  141 
 142 
Methods  143 
The ÆSOP-10 Study 144 
The present analysis included baseline neuropsychological, sociodemographic and clinical data from 145 
ÆSOP-10 (Aetiology and Ethnicity in Schizophrenia and Other Psychoses), a 10-year longitudinal 146 
follow-up, population-based study of first-episode psychosis (FEP) (Fearon et al. 2006; Morgan et al. 147 
2006). The study identified all individuals aged 16–65 years with FEP [codes F20–F29 and F30–F33 in 148 
the International Classification of Diseases, 10th Revision (ICD-10) manual (World Health 149 
Organisation: WHO, 1992a)], who presented to specialist mental health services in tightly defined 150 
catchment areas in Southeast London, Nottingham and Bristol between September 1997 and August 151 
2000. Exclusion criteria were previous contact with health services for psychosis, organic causes of 152 
psychotic symptoms, transient psychosis due to acute intoxication (as defined by ICD–10) and IQ<50. 153 
[Due to the primary focus of this analysis on neuropsychological functions, we used a higher threshold 154 
of inclusion herein: IQ>69, as assessed by the Wechsler Intelligence Scale-Revised) (WAIS-R) 155 
(Wechsler, 1981)]. The study further included a random sample of community controls with no past 156 
or present psychotic disorder, recruited using mainly a sampling method that matched cases and 157 
controls by area of residence. Across the three centres, 568 cases with consensus diagnoses of 158 
psychotic illness who met the study inclusion criteria, and 412 community controls, were identified. 159 
Patients provided detailed contact information for themselves, their General Practitioners (GPs) and 160 
relatives, and consent to be re-contacted for follow-up. Ethical approvals for the baseline and follow-161 
up studies were obtained from local research ethics committees. Detailed overviews of the ÆSOP 162 
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study design and procedures have been published elsewhere (Fearon et al. 2006; Morgan et al. 2006; 163 
Morgan et al. 2014; Demjaha et al. 2017). 164 
 165 
Baseline Assessment of Sociodemographic and Clinical Characteristics 166 
Sociodemographic data were collected by interviews with the participants using the Medical Research 167 
Council Sociodemographic Schedule (Mallett, 1997). Information gaps were filled using additional 168 
data sources, including case notes and other informants. Clinical data were collected as soon as 169 
possible after first contact with psychiatric services using the Schedules for Clinical Assessment in 170 
Neuropsychiatry (SCAN; WHO, 1992b). The SCAN incorporates the Present State Examination (PSE) - 171 
Version 10, which was used to elicit symptom-related data at presentation. Where a patient interview 172 
was not possible, case notes and, when available, information from informants, were used to 173 
complete the SCAN Item Group Checklist. Baseline symptom scores were further subjected to factor 174 
analysis, giving rise to five psychopathological dimensions: manic, reality distortion, negative, 175 
depressive and disorganization symptom dimensions (for full details, see Demjaha et al. 2009). 176 
Patients’ ICD–10 diagnoses were determined using the SCAN data on the basis of consensus meetings 177 
involving a principal investigator (PI) and other members of the research team with satisfactory 178 
interrater reliability (kappa values ranged from 0.63 to 0.75, P<0.001). Duration of untreated 179 
psychosis (DUP) was defined as the period from the onset of psychosis to first contact with statutory 180 
mental health services (for full details, see Morgan et al. 2006). Data on illicit substance use before 181 
first presentation to mental health services were collected retrospectively using an ad hoc secondary 182 
data collection schedule, which collated data on prevalence and type of illicit substance use from 183 
relatives or carers, from the SCAN (WHO, 1992b) and from clinical case notes. Controls were screened 184 
for psychosis using the Psychosis Screening Questionnaire (Bebbington & Nayani, 1995). Those with 185 
a positive rating were further assessed using the SCAN (WHO, 1992b) and, where appropriate, 186 
excluded. 187 
 188 
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Baseline Neuropsychological Assessment 189 
The present analysis included neuropsychological data collected at baseline using the National Adult 190 
Reading Test-Revised (NART-R) (Nelson & Willison, 1991), assessing premorbid intelligence; the 191 
Vocabulary, Comprehension, Block Design and Digit Symbol subtests of the WAIS-R (Wechsler, 1981), 192 
assessing verbal and non-verbal intelligence; trials 1-5 and 7 of the Rey Auditory Verbal Learning Test 193 
(RAVLT) (Spreen & Strauss, 1991), assessing immediate and delayed verbal recall and learning; the 194 
immediate Visual Reproduction trials of the Wechsler Memory Scale – Revised (WMS-R) (Wechsler, 195 
1987), assessing visual memory; the Trail Making A (Reitan, 1958), Trail Making B (Reitan, 1958) and 196 
Letter-Number Span (Gold et al. 1997) tests of processing speed, working memory and executive 197 
function; and Category and Letter Verbal Fluency (category: ‘body parts’, ‘fruits’ and ‘animals’; letter: 198 
F, A, S), assessing verbal ability and executive control.  199 
 200 
Follow-up Clinical Assessment 201 
At approximately 10 years after inclusion, we made an attempt to trace, re-contact and re-assess 557 202 
ÆSOP participants with psychosis, who had initially been identified in the Southeast London and 203 
Nottingham centres. Using an extended version of the WHO Life Chart Schedule (LCS) (WHO, 1992c) 204 
and a Medication History Timeline, comprehensive information on psychopathology, all prescribed 205 
antipsychotic medications (start and end date, dosage, adherence, reasons for change or 206 
termination), substance use and contact with mental health services was collected and rated for the 207 
entire follow-up period using a wide range of information sources: medical case records, follow-up 208 
interview with participant or informants (where possible), treating clinicians, ward and community 209 
prescriptions, medication charts and clinical documentation (including, where available, reports of 210 
drug level testing, and correspondence from the prescribing clinician/to general practitioners). Using 211 
the above sources, adherence to each prescribed antipsychotic throughout the period it was 212 
prescribed was rated on a three-point scale (1: 0-33%; 2: 34-67%; 3: 68-100%), using 68% as cut-off 213 
for ‘adherence’. Presence of symptoms at follow-up was further assessed using the Scan - Version 2 214 
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(WHO, 1994). Based on all available information, case histories were reconstructed for the entire 215 
follow-up period to complete all sections of the Life Chart. A detailed overview of the follow-up 216 
clinical assessment procedures has been published elsewhere (Morgan et al. 2014; Demjaha et al. 217 
2017). 218 
 219 
Representativeness of the Follow-Up Sample 220 
Of the 557 cases who were initially recruited, 434 (78%) underwent follow-up assessments. There 221 
were no marked differences in gender, ethnicity, duration of untreated psychosis, or diagnosis 222 
between the cases who underwent follow-up assessments and those who were lost to follow-up, 223 
except that the follow-up sample was younger (t=2.5; P=0.02).  224 
 225 
Criteria for Treatment Response and Treatment Resistance 226 
‘Response to treatment’ was defined as a state of no or mild symptoms (SCAN score<2), not 227 
interfering with daily functioning, lasting at least 6 months (Andreasen et al. 2005). In line with 228 
National Institute for Health and Care Excellence (NICE) criteria (National Institute for Health and Care 229 
Excellence, 2014), patients were classified as ‘Treatment Resistant’ (TR), if, despite recorded 230 
adherence to medication, they continued to show positive symptoms of at least moderate severity 231 
(SCAN score≥2) following two sequential trials of antipsychotic medication at a daily dose of 400–600 232 
mg of chlorpromazine equivalence, each lasting at least 4 weeks. Patients were classified as 233 
‘Treatment Resistant from Illness Onset’ (TRO) if they met resistance criteria after the first two trials 234 
of antipsychotic medication, and as ‘Delayed Onset Treatment Resistant’ (DOTR), if such criteria were 235 
met after a period of response to treatment. An individual meeting treatment resistance criteria, but 236 
later meeting treatment response criteria, would have been classified as treatment resistant. 237 
However, the ÆSOP-10 Study did not identify individuals whose response to medication improved 238 
during the course of illness. Of the 50 patients who received clozapine (by definition treatment 239 
resistant), 14 (28%) were clozapine responders, 12 (24%) were clozapine resistant, and the remaining 240 
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24 (48%) could not be classified, due to a suboptimal clozapine trial or insufficient clinical and 241 
response data (Demjaha et al. 2017). 242 
 243 
Representativeness of the Follow-Up Sample that was evaluated for Treatment Response 244 
Of the 434 cases who were assessed at follow-up, 212 (49%) met criteria for treatment response, 74 245 
(17%) met criteria for treatment resistance (of whom 62: 84% were TRO) and 37 (9%) had never 246 
received an adequate trial of antipsychotic medication and could not be included in either category. 247 
The remaining 111 participants (26%) had incomplete clinical information documentation and could 248 
not be classified. Cases with complete information did not differ notably from the remainder of the 249 
follow-up sample in terms of age, gender, ethnicity, DUP or diagnosis (Demjaha et al. 2017).  250 
 251 
Statistical Analysis  252 
Data Reduction and Generation of Composite Neuropsychological Scores 253 
To avoid the caveats of multiple testing and of experimenter assumptions during the grouping of 254 
cognitive tasks into overarching constructs (e.g. executive function), we reduced an original set of 13 255 
neuropsychological variables to a small number of components, using Principal Component Analysis 256 
(PCA) with promac oblique rotation in Stata/MP 14.0 (37stataCorp, 2015). This was performed on the 257 
present analytic cohort, i.e. 402 ÆSOP participants (145 cases, 257 controls) with available 258 
neuropsychological data at baseline (all participants), and with entire case history reconstruction at 259 
the 10-year follow-up (cases only). Where appropriate, variables were inverse transformed to achieve 260 
normality of distribution. The selected cut-off for the variable loadings on the PCA components was 261 
0.30, in line with recommendations that this has practical significance for sample sizes of at least 350 262 
(Hair et al. 1998, p. 112). The oblique method was preferred over the varimax solution for its superior 263 
capacity to identify a simple factorial structure, particularly in datasets where the latent traits are 264 
correlated (Finch, 2006). The Kaiser-Meyer-Olkin (KMO) test of sampling adequacy was used to 265 
determine the factorability of the data. To generate composite neuropsychological scores (each 266 
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reflecting a participant’s composite ability across variables with primary loadings on a certain 267 
component), we estimated PCA scores using Stata's predict command with the score option 268 
immediately after the PCA command. The PCA scores are expressed in standardized units based on 269 
linear combinations of the retained components. 270 
 271 
Comparison of Composite Neuropsychological Scores across Study Groups 272 
Statistical analysis was performed in Stata/MP 14.0 (37stataCorp, 2015). Each of the main and 273 
sensitivity (see below) analyses was a multivariable regression analysis with robust standard errors, 274 
comparing selected study groups or subgroups in each composite neuropsychological score. All main 275 
and sensitivity analyses co-varied for sociodemographic and (where appropriate) clinical variables 276 
that were associated with each composite score at P<0.1 in preliminary univariable linear regression 277 
analyses (see Supplementary Table S1). Composite neuropsychological scores were compared across 278 
the treatment-resistant (TR), treatment-responder (non-TR) and community control groups, as well 279 
as between TR and non-TR cases in the full patient sample and in the diagnostic subgroup with 280 
schizophrenia.  281 
Performing separate analyses for cases who were Treatment Resistant from Illness Onset 282 
(TRO) and those who had Delayed-Onset Treatment Resistance (DOTR) would enhance the 283 
interpretability of our findings. However, this was not possible due to the small size of the DOTR 284 
subgroup (n=6). We instead repeated all data analytic steps in sub-analyses which excluded the DOTR 285 
patients. 286 
 287 
Sensitivity Analysis 288 
All main statistical analyses uniformly controlled for the effects of ethnicity and education. However, 289 
as the TR group had a higher proportion of Black ethnic minorities (47%) than the non-TR (24%) and 290 
control (14%) groups (see Results and Table 1), it was important to further address potential 291 
confounding influences of language in our analysis. We therefore assessed the sensitivity of our 292 
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findings to excluding all participants who had been born outside the UK, regardless of ethnicity or 293 
first language (n=58; 15 non-TR, 6 TR, 37 controls). This left in the analysis an all-UK-born sample who 294 
had attended compulsory schooling in the UK.  295 
  296 
Missing Data 297 
The level of completeness of sociodemographic and clinical information at the time of the baseline 298 
neuropsychological assessment was high (96-100% for socio-demographic variables and 82-100% for 299 
clinical variables). The high level of completeness at baseline is partly attributable to the temporal 300 
proximity of the sociodemographic, clinical and neuropsychological assessments, which were 301 
typically completed within a few days of each other. Antipsychotic medication history was re-302 
constructed in detail at the 10-year follow up. Exact recording of neuropsychological testing dates at 303 
baseline was available only in a subset of cases, allowing us to map the participants’ complex 304 
medication histories onto the dates of their neuropsychological testing in a subgroup of 75 cases 305 
(52%, 57 non-TR, 18 TR). Detailed information on the medication received by this subgroup is 306 
presented in Supplementary Table S2.  307 
 308 
Results 309 
Representativeness of the Analytic Cohort 310 
Of the 286 cases who were classified in terms of treatment response at follow-up (see Methods), 136 311 
cases (48%) lacked neuropsychological data at baseline, and 5 (2%) had IQ<70, leaving 113 non-TR 312 
cases, 32 TR cases (of whom 26: 81% were TRO), and 257 community controls in the present analysis. 313 
There were no notable differences in age, gender, DUP or diagnosis between the patient analytic 314 
cohort (n=145), and those who lacked neuropsychological data at baseline or met exclusion criteria 315 
(N=141). However, the patient analytic cohort (treatment-responders and TR cases combined) 316 
comprised a lower proportion of black ethnic minorities (29%) than the cases who lacked 317 
neuropsychological data or who met exclusion criteria (51%; Chi-Square=14.563, P=0.001).  318 
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  319 
Sociodemographic and Clinical Characteristics 320 
The sociodemographic and clinical characteristics of the analytic cohort are presented in Table 1. 321 
Compared to controls, both patient groups were younger, had fewer years of education, and a higher 322 
proportion of male and Black participants (P<0.01-0.0001). Compared to treatment-responders, TR 323 
cases were younger, had a higher proportion of male and Black participants, a higher score on the 324 
negative symptom dimension, and a longer duration of untreated psychosis (P<0.05-0.0001) (Table 325 
1). The two patient groups did not differ statistically significantly in illicit substance use [positive 326 
lifetime history present in 27 (25%) non-TR- and in 4 (12.5%) TR participants; Chi-Square=2.237, 327 
P=0.135)]. 328 
 329 
Data Reduction and Estimation of Composite Neuropsychological Scores 330 
The PCA gave rise to a three-component solution (eigenvalues 1.20-5.78) accounting for 0.65% of the 331 
variance. The results of the promax rotation of the solution are presented in Table 2. NART IQ, WAIS-332 
R Vocabulary, WAIS-R Comprehension, Phonological Verbal Fluency and Semantic Verbal Fluency 333 
showed primary loadings (0.306-0.520) on Component 1, which was labelled Verbal Intelligence and 334 
Fluency. WAIS-R Block Design, WAIS-R Digit Symbol and Trail Making (A & B) showed primary loadings 335 
(0.332-0.565) on Component 2, which was labelled Visuospatial Ability and Executive Function. The 336 
immediate and delayed recall trials of the RAVLT showed primary loadings (0.598-0.698) on 337 
Component 3, which was labelled Verbal Memory and Learning. The Kaiser-Meyer Olkin measure of 338 
sampling adequacy indicated that the sample had very high factorability (KMO=0.875). Composite 339 
neuropsychological scores (PCA scores) were generated for the three components and used in the 340 
remaining analyses. 341 
 342 
Comparison of Composite Neuropsychological Scores across Study Groups 343 
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Tables 3 and 4 present the means and standard deviations of the composite neuropsychological 344 
scores in the three study groups, as well as the results and effect sizes of selected group comparisons. 345 
Figure 1 presents the distribution of the composite scores in Verbal Intelligence and Fluency in the 346 
full analytic cohort divided by study group. Both patient samples were impaired in all composite 347 
scores compared to controls (P≤0.001) (Table 3), with moderate to large effect sizes in the treatment-348 
responsive patients and with large to very large effect sizes in the treatment-resistant cohort.  349 
Compared to non-TR patients, the TR cases performed worse in Verbal Intelligence and 350 
Fluency in all main analyses (P<0.05) (Tables 3 & 4; Figure 1), sub-analyses (P<0.01-0.001) (excluding 351 
DOTR case: Supplementary Tables S3-S4), and sensitivity analyses (P<0.05) (excluding non-UK-born 352 
participants: Supplementary Tables S5-S6).  353 
In the schizophrenia subgroup, TR cases performed worse than non-TR patients in 354 
Visuospatial Ability and Executive Function (P<0.05) (Table 4), but the finding did not persist in our 355 
sub-analyses or sensitivity analyses (Supplementary Tables S3-S6).     356 
 357 
 358 
Discussion 359 
Summary of Findings 360 
Our analysis of baseline data from the ÆSOP-10 longitudinal, population-based study of first-episode 361 
psychosis provides a snapshot of neuropsychological function at the earliest stages of treatment-362 
resistant psychosis. Both treatment-resistant and treatment-responsive patients with schizophrenia 363 
and other psychoses showed generalised neuropsychological deficits in verbal intelligence and 364 
fluency, visuospatial abilities and executive function, and verbal memory and learning compared to 365 
community controls. Furthermore, treatment-resistant patients showed, on average, impairments in 366 
verbal intelligence and fluency compared to treatment responders, replicating previous findings 367 
(Joober et al. 2002; Frydecka et al. 2016). This differential was an enduring finding of our analyses – 368 
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evident for individuals with schizophrenia, those with any psychoses, psychotic and schizophrenia 369 
patients born in the UK, and after excluding cases with delayed-onset treatment resistance. 370 
 371 
Methodological Considerations 372 
This is the first longitudinal, population-based study of first-episode psychosis that compared baseline 373 
neuropsychological function across patients with longitudinally-defined TR- and non-TR psychosis and 374 
community controls. The study draws on unique methodological advantages: The epidemiological 375 
source and robust size of the combined patient and community control groups increased the 376 
representativeness of our cohort and generalisability of our findings, whilst facilitating stringent 377 
statistical controls (including a sensitivity analysis) for a wide array of clinical, sociodemographic, and 378 
language confounders. Analysing neuropsychological data from the first episode minimised 379 
information bias (i.e. examiners did not know the participants’ treatment response status at the time 380 
of testing) and reduced differentiation in clinical features between the two patient groups. 381 
Specifically, in contrast to all previous neuropsychological studies of TRS (Joober et al. 2002; de 382 
Bartolomeis et al. 2013; Bourque et al. 2013; Anderson et al. 2015; Frydecka et al. 2016; Iasevoli et 383 
al. 2016), our patient groups did not seem to differ notably in treatment profiles or medication doses 384 
at the time of testing (based on a subgroup analysis). These aspects served to further reduce 385 
confounding in our analysis.  386 
Methodological limitations of our study include loss to follow up; limitations on clinical data 387 
accuracy associated with case history reconstruction; the availability of baseline neuropsychological 388 
testing dates for only a subgroup of patients; the lack of screening for family history of psychosis in 389 
community controls; and the moderate size of the treatment-resistant cohort. A deficit in verbal 390 
intelligence and fluency in TR patients compared to responders was a highly consistent finding across 391 
our main analyses, sub-analyses and sensitivity analyses. However, we cannot exclude the possibility 392 
that additional deficits are integral to TR psychosis, particularly in relation to schizophrenia (discussed 393 
below). Our selected cut-off for factor loadings (0.30) is among the lowest reported in the literature 394 
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(Peres-Neto et al. 2003), and may have reduced the clarity of the PCA components. Using a 0.40 cut-395 
off would not have changed the pattern of findings (data available upon request). Finally, our analyses 396 
included baseline diagnoses. As with the extended ÆSOP sample (Heslin et al. 2003), most 397 
schizophrenia patients (77%) and 40% of those with ‘other’ diagnoses in our analytic cohort were 398 
classified as having schizophrenia at 10 years. Using diagnostic classifications at follow up, 31.5% of 399 
schizophrenia patients would have been classified as TR compared to 35.8% using baseline diagnoses. 400 
  401 
Treatment-Resistant Psychosis as a Severe Neurodevelopmental Variant of Psychosis 402 
The neurodevelopmental theory of schizophrenia posits the existence of a neurodevelopmental 403 
subtype of schizophrenia, which is the end product of aberrant neurodevelopmental processes 404 
unfolding from conception or early life (Murray et al. 1992). It has been suggested that primary TRS 405 
has a distinct neurodevelopmental origin, while secondary TRS may arise through the induction of 406 
dopamine super-sensitivity, or after periods of relapse, although a later emergence of an intrinsic 407 
treatment resistance, or a combination of underlying factors cannot be ruled out (Lally et al. 2016; 408 
Gillespie et al. 2017; Demjaha et al. 2017). The clinical and demographic profiles of the treatment-409 
resistant cases in the present study largely encapsulate the defining features of ‘neurodevelopmental 410 
schizophrenia’ – younger, ‘more male’, with an earlier age of onset, more severe negative symptoms, 411 
more severe cognitive impairment and a longer duration of untreated psychosis (Murray et al. 1992). 412 
Three further observations suggest a pathogenic origin for the observed verbal deficit in the 413 
treatment-resistant group compared to treatment-responsive individuals. Firstly, the impairment was 414 
established by the first episode, arguing against the deficit being caused by non-remitting psychosis. 415 
Secondly, Vocabulary and NART-R, two tasks with primary loadings on Verbal Intelligence and Fluency, 416 
are reliable tests of premorbid ability, and are both resistant to brain pathological changes (de Oliveira 417 
et al. 2014; Bright et al. 2002). Finally, the pattern of deficits in verbal intelligence and fluency was 418 
accentuated (deficits were significant at a lower level of statistical significance) after removing cases 419 
with secondary treatment resistance.  420 
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 Black participants were over-represented among treatment resistant patients. Although 421 
Black ethnicity is not a defining feature of ‘neurodevelopmental schizophrenia’ (Murray et al. 1992), 422 
the finding is in keeping with evidence that treatment resistance is associated with early first contact 423 
with psychiatric services (<20 years), and more so in Black (OR 3.71) than in White (OR 1.60) patients 424 
(Lally et al. 2016). Indeed, a closer look at our data revealed that only 9.4% of White patients, but 425 
21.4% of Black patients had a first contact with psychiatric services before age 20, which may have 426 
increased disproportionately the outcome of treatment resistance in the Black ethnic group. 427 
 428 
Treatment-Resistant Schizophrenia  429 
An additional deficit in visuospatial ability and executive function emerged in TR- compared to non-430 
TR patients in the schizophrenia subgroup.  This finding did not generalise to the ‘all-diagnoses’ group 431 
and did not persist in our sub-analyses or sensitivity analyses. The finding is consistent with evidence 432 
that deficits in executive function, processing speed and verbal memory, albeit less salient in other 433 
diagnostic categories of psychosis, are prototypical of schizophrenia (Kravariti et al. 2009a; Kravariti 434 
et al. 2009b; Zanelli et al. 2010). As the size of the schizophrenia subgroup in the present study was 435 
modest, it is important to explore the significance of executive function and verbal memory deficits 436 
in treatment resistant schizophrenia in larger studies. 437 
 438 
Integrating Neurodevelopmental and Glutamatergic Hypotheses of Treatment-Resistant Psychosis 439 
Some recent findings implicate glutamate rather than dopamine as the primary neurotransmitter 440 
system impaired in treatment-resistant schizophrenia (Demjaha et al. 2012; Demjaha et al. 2014; 441 
Gillespie et al. 2017). Glutamate plays an important role in several language-related 442 
neurodevelopmental processes. This highlights the possibility that core deficits in verbal intelligence 443 
and fluency, a neurodevelopmental aetiology, and a primary glutamatergic dysfunction may converge 444 
in a single model of treatment-resistant psychosis. Several lines of evidence support this possibility: 445 
pre-reading language abilities (e.g. phonological processing) show significant correlations with 446 
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glutamate in the anterior cingulate of healthy preschool-aged children (Lebel et al. 2016); 447 
microdeletions in glutamate receptors have been implicated in developmental delays predominantly 448 
affecting language and fine motor skills (Takenouchi et al. 2014); the high-risk metabotropic 449 
glutamate receptor 3 (GRM3) haplotype is associated with schizophrenia, as well as with deficits in 450 
verbal fluency and verbal list-learning (Spangaro et al. 2012); and poor-functioning subjects at ultra-451 
high-risk for psychosis show a negative relationship between thalamic glutamate levels and 452 
prefrontal-striatal activation during a verbal fluency task (Allen et al. 2015).  453 
 454 
Clinical and Research Implications 455 
Neuropsychological deficits weigh disproportionally on the psychosocial and functional toll of 456 
psychosis (Kaneda et al. 2010; Shamsi et al. 2011; Iasevoli et al. 2016). Encouragingly, verbal fluency 457 
and executive function deficits, which differentiated TR from non-TR patients in the present study, 458 
do not seem refractory to pharmacological interventions. Indeed, there is strong evidence that 459 
clozapine improves attention and verbal fluency, and moderate evidence that it improves some types 460 
of executive function (Meltzer & McGurk, 1999; Woodward et al. 2005). In the only studies to report 461 
equivalent verbal performances in TRS- and non-TRS patients to date, TR cases were uniformly 462 
treated with clozapine (Anderson et al. 2015; Bourque et al. 2013). These findings re-iterate the 463 
necessity of timely detection and tailored pharmacological interventions as early as possible in the 464 
course of treatment-resistant psychosis (Lally & MacCabe, 2016). They further highlight the 465 
importance of neuropsychological constructs in designing multimodal research and clinical 466 
approaches to improving prognosis and personalised treatment (Gilbert et al. 2014).  467 
 468 
Conclusion 469 
A constitutional deficit in verbal intelligence and fluency, significantly exceeding – at a group level - 470 
the levels manifest in the general population of patients with psychoses, is a phenotypic indicator of 471 
treatment-resistant psychosis. Our findings are in keeping with emerging evidence that treatment-472 
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resistant psychosis is a pathogenically distinct and severe variant, embedded in aberrant 473 
neurodevelopmental processes. 474 
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Table 1 Sociodemographic and Clinical characteristics in the Treatment-Responder, Treatment-Resistant and Community Control Groups 678 
  TREATMENT-RESPONDER 
(n=113) 
 TREATMENT-RESISTANT 
(n=32) 
 COMMUNITY CONTROL 
(n=257) 
   
       
  Mean SD  Mean SD  Mean SD  F P≤ 
Education (years) a  12.60 2.36  12.10 1.90  13.26 2.55  5.97 0.003 
Age at Assessment (years) b  30.75 10.60  26.63 9.07  39.73 13.16  62.81 0.0001 
Age at Illness Onset (years)  30.23 10.67  25.41 9.02  - -  5.71 0.018 
Days of Untreated Psychosis  197.58 528.52  633.04 1097.00  - -  4.81 0.030 
Antipsychotic Defined Daily Dose (DDD) c 334.66 238.56  427.81 229.71  - -  1.89 0.174 
Reality Distortion  3.41 2.55  4.00 3.24  - -  0.70 0.405 
Disorganisation  0.69 0.96  0.83 0.82  - -  0.52 0.471 
Negative Symptoms  1.21 1.76  2.38 2.62  - -  4.36 0.039 
Mania  1.94 2.73  1.63 2.32  - -  0.33 0.568 
Depression  1.43 1.85  1.09 1.84  - -  0.70 0.405 
  N %  N %  N % Pearson χ2 P≤ 
Gender: d           17.39 0.0001 
Male  63 55.8  25 78.1  109 42.4    
Female  50 44.2  7 21.9  148 57.6    
Ethnicity: e, f           Fisher’s f 0.001 
White  72 63.7  13 40.6  211 82.1    
Black  27 23.9  15 46.9  37 14.4    
Other  14 12.4  4 12.5  9 3.5    
Level of Completed Education: g           7.604 0.107 
School  65 63.1  19 67.9  131 51.4    
Further  19 18.4  7 25.0  69 27.1    
Higher  19 18.4  2 7.1  55 21.6    
Diagnosis: f            Fisher’s f 0.004 
Schizophrenia  43 38.1  24 75.0  - -    
Bipolar Disorder or Mania  24 21.2  2 6.3  - -    
Depressive Psychosis  18 15.9  2 6.3  - -    
Other Psychotic Disorder  28 24.8  4 12.5  - -    
Antipsychotic Type c, f           Fisher’s f 0.725 
Typical  22 38.6  8 44.4  - -    
Atypical   33 57.9  9 50.0  - -    
Combination of Typical & Atypical  2 3.5  1 5.6  - -    
a TR, non-TR<CC, b TR, non-TR<CC, TR<non-TR. c Data was available for a subset of 75 cases (52%). d Proportion Male: TR, non-TR>CC; TR>non-TR. Proportion Black: TR, non-TR>CC; TR>non-TR. 679 
f As the statistical assumptions for the chi-square test were violated, Fisher’s Exact Test was performed. g Level of completed education was missing for 16 participants (4%).  680 
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Table 2 Obliquely Rotated Component Loadings 1 for 13 Neuropsychological Variables in the 681 
analytic cohort 2 (n=402) 682 
 683 
 Component Loadings 
 1  2  3 
WAIS-R Vocabulary 0.520  0.103  0.025 
WAIS-R Comprehension 0.487  0.124  0.067 
NART-R IQ 0.485  0.045  -0.017 
Phonological Verbal Fluency (Letter) 0.322  -0.122  -0.169 
Semantic Verbal Fluency (Category) 0.306  -0.178  -0.119 
Trail Making A 0.113  0.565  0.113 
Trail Making B 0.064  0.505  0.030 
WAIS-R Digit Symbol 0.027  0.416  0.016 
WAIS-R Block Design 0.019  0.332  0.133 
RAVLT Trials 1-5 0.090  0.046  0.598 
RAVLT Trial 7 -0.047  0.052  0.698 
WMS-R Visual Reproduction (Total Score) -0.052  -0.254  0.236 
Letter-Number Span 0.203  -0.126  0.155 
Abbreviations: NART-R: National Adult Reading Test-Revised; RAVLT: Rey Auditory Verbal Learning Test; WAIS-R: Wechsler 684 
Adult Intelligence Scale-Revised;  685 
1 Variables with primary loadings of >0.30 are set against a grey background, and high loadings of >0.50 are highlighted in 686 
red font. 2 The sample included participants who had undergone neuropsychological testing at baseline, had IQ ≥70, and 687 
could be classified (in the case of patients, retrospectively, i.e. at the 10-year follow-up) as treatment responders (n=113), 688 
treatment resistant (n=32), or community controls (n=257). 689 
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Table 3 Comparison a of Composite Neuropsychological Scores across the Treatment-Responder, Treatment-Resistant and Community Control Groups 703 
  RESPONDER  TREATMENT-RESISTANT  
COMMUNITY 
CONTROL 
   
 (n=113)  (n=32)  (n=257)    
         REGRESSION MODEL a 
 Mean SD  Mean SD  Mean SD  F(D.F.) P≤ 
VERBAL INTELLIGENCE & FLUENCY -0.81 1.81  -1.91 1.68  0.59 1.64  40.15(7, 386) 0.0001 
VISUOSPATIAL ABILITY & EXECUTIVE FUNCTION -0.71 1.79  -1.29 2.00  0.47 1.66  37.12(7, 387) 0.0001 
VERBAL MEMORY & LEARNING -0.37 1.29  -1.13 1.43  0.30 1.37  21.99(7, 386) 0.0001 
            
         POST-HOC COMPARISONS a 
 
 
 
Cohen’s d b 
 
 
 
Cohen’s d c 
   RESPONDER VS. CONTROL 
TREATMENT 
RESISTANT VS. 
CONTROL 
RESPONDER VS. 
TREATMENT 
RESISTANT 
 d 95% CI d 95% CI   t P≤ t P≤ t P≤ 
VERBAL INTELLIGENCE & FLUENCY -0.83 -1.06 -0.60 -1.52 -1.91 -1.13   -4.12 0.001 -5.22 0.001 2.35 0.019 
VISUOSPATIAL ABILITY & EXECUTIVE FUNCTION -0.69 -0.92 -0.47 -1.04 -1.41 -0.66   -6.60 0.001 -5.32 0.001 1.44 0.150 
VERBAL MEMORY & LEARNING -0.50 -0.72 -0.27 -1.04 -1.42 -0.66   -4.36 0.001 -4.38 0.001 1.94 0.053 
               
a The effect of Group (Treatment Responder, Treatment Resistant, Community Control) on each Composite Score was examined using multivariable regression analysis with 704 
robust standard errors, co-varying for demographic variables that emerged as significant (P<0.05) or suggestive (P<0.1) predictors of each Composite Score in preliminary 705 
univariable linear regression analyses (Supplementary Table S1): Age, Ethnicity, Years of Education (all Composite Scores) and Gender (Verbal Intelligence & Fluency; Verbal 706 
Memory & Learning). b Standardised mean difference the between treatment-responder and community-control groups; c Standardised mean difference between the 707 
treatment-resistant and community-control groups.       708 
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Table 4 Comparison of Composite Neuropsychological Scores between the Treatment-Responder and Treatment-Resistant Groups 714 
  INDEPENDENT EFFECT OF GROUP (RESPONDER VS. TREATMENT RESISTANT)  
  Coefficient  Stand. Err.  95% CI  t P≤  
    
  All Diagnoses  
    
VERBAL INTELLIGENCE & FLUENCY a  -0.76  0.32  -1.40 -0.12  -2.35 0.020  
VISUOSPATIAL ABILITY & EXECUTIVE FUNCTION b  -0.70  0.57  -1.84 0.45  -1.23 0.226  
VERBAL MEMORY & LEARNING c  -0.40  0.52  -1.46 0.66  -0.76 0.453  
            
 Schizophrenia  
   
VERBAL INTELLIGENCE & FLUENCY a  -0.96  0.38  -1.72 -0.20  -2.56 0.014  
VISUOSPATIAL ABILITY & EXECUTIVE FUNCTION b  -1.55  0.61  -1.95 0.28  -2.55 0.019  
VERBAL MEMORY & LEARNING c  -0.35  0.74  -1.90 1.20  -0.48 0.640  
            
a The effect of Group (Treatment Responder vs. Treatment Resistant) on Verbal Intelligence & Fluency was examined using multivariable regression analysis with robust standard errors, 715 
co-varying for demographic and clinical variables that emerged as significant (P<0.05) or suggestive (P<0.1) predictors of Verbal Intelligence & Fluency in preliminary univariable linear 716 
regression analyses (Supplementary Table S1): Age, Gender, Ethnicity, Years of Education, Negative Symptoms, Mania and Depression. The analysis for ‘All Diagnoses’ additionally co-717 
varied for ‘Diagnosis’. 718 
b The effect of Group (Treatment Responder vs. Treatment Resistant) on Visuospatial Ability & Executive Function was examined using multivariable regression analysis with robust 719 
standard errors, co-varying for demographic and clinical variables that emerged as significant (P<0.05) or suggestive (P<0.1) predictors of Visuospatial Ability & Executive Function in 720 
preliminary univariable linear regression analyses (Supplementary Table S1): Age, Ethnicity, Years of Education, Age at Illness Onset,  Negative Symptoms, Mania, Medication Dose 721 
(expressed in Defined Daily Dose units) and Illicit Substance Use [positive/negative lifetime history of, based on information collected from relatives or carers, the Schedules for Clinical 722 
Assessment in Neuropsychiatry (SCAN; WHO, 1992b), clinical case notes and an extended version of the WHO Life Chart Schedule (WHO, 1992c)]. The analysis for ‘All Diagnoses’ 723 
additionally co-varied for ‘Diagnosis’. 724 
c The effect of Group (Treatment Responder vs. Treatment Resistant) on Verbal Memory & Learning was examined using multivariable regression analysis with robust standard errors, 725 
co-varying for demographic and clinical variables that emerged as significant (P<0.05) or suggestive (P<0.1) predictors of Verbal Memory & Learning in preliminary univariable linear 726 
regression analyses (Supplementary Table S1): Age, Gender, Ethnicity, Years of Education, Duration of Untreated Psychosis, Reality Distortion, Negative Symptoms, Mania and 727 
Medication Dose (expressed in Defined Daily Dose units). The analysis for ‘All Diagnoses’ additionally co-varied for ‘Diagnosis’. 728 
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